Bessemer Group’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Bessemer Group’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-425	Closed	-$4K	–	2783
2024 Q4	$4K	Hold	425	–	–	﹤0.01%	2100
2024 Q3	$1K	Buy	+425	New	+$1.32K	﹤0.01%	2598

Other funds holding PSTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Bessemer Group's PSTX Position: Q1 2025 in Review

Bessemer Group sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 425 shares — an estimated $4K sold.

Bessemer Group first reported a position in PSTX in Q3 2024 and held it in 2 quarters. The position peaked at $4K in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

Bessemer Group reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Bessemer Group sold 425 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $4K.
Bessemer Group first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2024 and held it in 2 quarters.
Bessemer Group's Poseida Therapeutics, Inc. Common Stock position peaked at $4K in Q4 2024.
1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Bessemer Group's 13F filing for Q1 2025, filed 23 Apr 2025.